The 84th Scientific Sessions will present the latest breakthroughs in diabetes, prevention, and care in a hybrid format for a global audience, including new results from several clinical trials.
“Attendees can expect an opportunity to meet with other like-minded diabetes professionals and discuss high-level science, the latest clinical, translational, and foundational research, and be able to network with colleagues from around the world,” said Scientific Sessions Meeting Planning Committee Chair Alice Y.Y. Cheng, MD, FRCPC.
More than 200 sessions and 1,400 posters will be presented from June 21-24 in Orlando, including symposia, panel discussions, debates, and Ask the Experts and professional education sessions. Several sessions each day will be livestreamed for online participants.
“There is so much that you will be able to gain from the knowledge that will be in the convention center, not just from the speakers, but from the posters, the networking, and simply from chatting with fellow diabetes enthusiasts,” Dr. Cheng said. “You’ll walk away inspired from all of that energy and interaction.”
Based on positive attendee feedback, changes to the meeting format instituted last year will carry over to this year’s Scientific Sessions.
“We will start off with a keynote lecture so that everyone begins the meeting together,” Dr. Cheng explained. “The Innovation Challenge was very popular, and that’s been brought back. We’re also having more debates and even more panels than we had last year because those were well appreciated. Features like the Year in Review symposium will continue, and we’ll have some exciting new data that’s being presented for the first time at the ADA from some large clinical trials.”
New trial data will be presented from:
- ATTEMPT, a study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in youth with type 1 diabetes;
- INHALE-3, a study of inhaled insulin in type 1 diabetes;
- TIGHT, a study of continuous glucose monitoring (CGM) versus usual care for type 2 diabetes in the hospital;
- CATALYST, a study of therapy for hypercortisolism in type 2 diabetes;
- FLOW, a study of semaglutide in diabetic kidney disease;
- STEP-HFpEF-DM trials, a study of semaglutide in heart failure with preserved ejection fraction;
- SELECT, new glycemic data from study of semaglutide in cardiovascular disease with elevated body mass index (BMI); and
- SURMOUNT OSA, a study of tirzepatide in obesity-related obstructive sleep apnea.
“As an attendee, I’m most excited to see the newest data and first-in-world presentations of new information,” Dr. Cheng said. “I’m also excited to see my friends from around the world because this is almost like a diabetes holiday celebration when people come from different parts of the world and get together as a family again.”
The program is organized into eight themes:
- Acute and Chronic Complications
- Behavioral Medicine/Clinical Nutrition/Education and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Beta-Cell Replacement
- Insulin Action/Molecular Metabolism
- Islet Biology/Insulin Secretion
- Obesity/Integrated Physiology
Participants have the opportunity to earn up to 29.5 continuing education credits to enhance their professional development. For more details on session offerings, visit the Online Planner.
Full, in-person meeting registration includes access to on-demand recordings of sessions through Aug. 26.
“With the push toward health equity and better access, the hybrid model fits into the belief that we need to share the best and most current scientific information with as many people as possible,” Dr. Cheng said.
Register Today for the 84th Scientific Sessions
Join us in Orlando for the 84th Scientific Sessions, June 21-24. Full in-person registration includes access to all of the valuable onsite content during the meeting and on-demand access to the virtual program June 25-Aug. 26. For those unable to join us in-person, we are planning a virtual program to allow as many people as possible to participate and learn about the latest advances in diabetes research, prevention, and care.